Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q2 FY2021 Earnings Presentation
25 slides from Camlin Fine Sciences's earnings presentation, Nov 13, 2020
Slide 1: Stock exchange intimation letter
13th November, 2020 To, To, BSE Limited, The Manager, 25, P. J. Towers, Listing Department, Dalal Street, National Stock Exchange of India Ltd., Mumbai – 400 001 Exchange Plaza, Bandra Kurla Complex, Ref: Company Scrip Code: 532834 Bandra (East), Mumbai‐ 400051 Ref: Symbol: CAMLINFINE || Series: EQ
Slide 2: Earnings Presentation H1 / Q2-FY21
EARNINGS PRESENTATION H1 / Q2-FY21
Slide 3: Snapshot
Snapshot One of the few vertically and backward Leading Manufacturers of Antioxidants in the 3rd largest producer of Vanillin in the integrated players world with more than 30 years of experience world Serving more than 80 countries with over Preferred Partner for manufacturing customized Strategic
Slide 4: About the Company
About the Company • In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror Total Operational Revenue (INR Mn) shareholding) the fine chemical business from Camlin Ltd. 10,491 • The Company has over 30 years of experience providing innovative solutions with a 8,922 competitiv
Slide 5: H1 / Q2-FY21 Financial Overview
H1 / Q2-FY21 FINANCIAL OVERVIEW
Slide 6: H1 / Q2-FY21 Financial and Operational Highlights
H1 / Q2-FY21 Financial and Operational Highlights Q2-FY21 Financial Highlights (Standalone): Q2-FY21 Financial Highlights (Consolidated): • Turnover: INR 1,468 Mn • Turnover: INR 2,568 Mn • EBITDA: INR 71 Mn • EBITDA: INR 336 Mn • EBITDA Margin : 4.84% • EBITDA Margin: 13.08% • Adjusted EBITDA*: INR
Slide 7: Q2-FY21 Standalone Income Statement (Ind-AS)
Q2-FY21 Standalone Income Statement (Ind-AS) Income Statement (Mn) Q2-FY21 Q2-FY20 Y-o-Y Q1-FY21 Q-o-Q Operational Revenue 1,468 1,435 2.3% 1,212 21.1% Total Expenses 1,397 1,255 11.3% 1,049 33.2% Operational EBITDA 71 180 (60.6)% 163 (56.4)% Operational EBITDA Margins (%) 4.84% 12.54% (770) Bps 13.
Slide 8: H1-FY21 Standalone Income Statement (Ind-AS)
H1-FY21 Standalone Income Statement (Ind-AS) Income Statement (Mn) H1-FY21 H1-FY20 Y-o-Y Operational Revenue 2,679 2,871 (6.7)% Total Expenses 2,446 2,554 (4.2)% Operational EBITDA 233 317 (26.5)% Operational EBITDA Margins (%) 8.70% 11.04% (234) Bps Adjusted EBITDA* 302 317 (4.7)% Adjusted EBITDA M
Slide 9: Q2-FY21 Consolidated Income Statement (Ind-AS)
Q2-FY21 Consolidated Income Statement (Ind-AS) Income Statement (INR Mn) Q2-FY21 Q2-FY20 Y-o-Y Q1-FY21 Q-o-Q Operational Revenue 2,568 2,223 15.5% 3,057 (16.0)% Total Expenses 2,232 1,922 16.1% 2,547 (12.4)% Operational EBITDA 336 301 11.6% 510 (34.1)% Operational EBITDA Margins (%) 13.08% 13.54% (4
Slide 10: H1-FY21 Consolidated Income Statement (Ind-AS)
H1-FY21 Consolidated Income Statement (Ind-AS) Income Statement (Mn) H1-FY21 H1-FY20 Y-o-Y Operational Revenue 5,626 4,824 16.6% Total Expenses 4,778 4,168 14.6% Operational EBITDA 848 656 29.3% Operational EBITDA Margins (%) 15.07% 13.60% 147 Bps Adjusted EBITDA* 968 669 44.7% Adjusted EBITDA Margi
Slide 11: Country Overview
COUNTRY OVERVIEW
Slide 12: CFS India
CFS India • R&D Centre at Tarapur that has developed many new Diphenol-downstream products • Shelf Life Solutions Development, Testing and Applications Lab at Mumbai that works on testing food formulations and blends for the food, pet food and animal nutrition industries • Provides technical experti
Slide 13: CFS Mexico
CFS Mexico • Acquire 65% stake in Dresen Quimica SAPI De CV, Mexico in May 2016 • Primarily manufactures Blends and Additives • Key customer segments: Oil, Poultry, Diary, Rendering,Aqua, Pet food, Swine,Vitamin Pre-mix • Total Market size is ~USD 200 Mn and CFS Mexico enjoys an overall market share
Slide 14: CFS Europe
CFS Europe Performance Chemicals • Acquired the manufacturing facility at Ravenna, Italy in 2011, which provides captive requirements of key raw materials i.e. Hydroquinone and Catechol • Capacity utilization achieved at 95% in FY19 • Considerable growth in EBITDA Margins & Profits due to favourable
Slide 15: CFS Brazil
CFS Brazil Shelf Life Solutions • Formed in 2013 for Blends and the production started in 2015 • Has an application lab in Indaiatuba – Brazil for customizing blends for Shelf-life Extension Solutions. • Handles distribution of bulk antioxidants and vanillin. • Key customer segments: Oil, Poultry, D
Slide 16: CFS Wanglong
CFS Wanglong • CFS along with CFS Europe acquired 51% stake in Ningbo Wanglong Flavours in 2017 which had an operational plant since 2011 • This acquisition makes CFS the 3rd largest producer of Vanillin • Located in Grade 1 Industrial zone in the city of Yuyao Zhejiang Province, China. • It manufac
Slide 17: CFS North America
CFS North America Shelf Life Solutions • Formed in October 2015 as a wholly owned subsidiary Market focus • Food - Bulk oils (synthetic antioxidants), Meat & poultry (natural antioxidants) • Pet food - Rendering for pet food (natural antioxidants), Rendering for animal feed (synthetic antioxidants)
Slide 18: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW
Slide 19: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY18 FY19 FY20 H1-FY21 Operational Income 4,050 5,481 5,798 2,679 Total Expenses 3,996 5,182 5,201 2,446 EBITDA 54 299 597 233 EBITDA Margin 1.33% 5.46% 10.30% 8.70% Depreciation 91 91 113 64 Finance Cost 236 203 281 145 Other Income 92 137
Slide 20: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY19 FY20 H1-FY21 Particulars (INR Mn) FY19 FY20 H1-FY21 EQUITY 3,474 3,768 4,367 Non-Current Assets 2,733 3,802 3,812 a) Equity Share Capital 121 121 121 a) Property, Plant and Equipment 789 686 2,419 b) Other Equity 3,353 3,647 4,246 b) Capital Work In
Slide 21: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY18 FY19 FY20 H1-FY21 Operational Income 7,228 8,922 10,491 5,626 Total Expenses 7,102 8,235 9,184 4,778 EBITDA 126 687 1,307 848 EBITDA Margin 1.74% 7.70% 12.46% 15.07% Depreciation 267 290 328 191 Finance Cost 284 367 431 187 Other Inc
Slide 22: Consolidated Balance Sheet
Consolidated Balance Sheet PARTICULARS (INR Mn) FY19 FY20 H1-FY21 PARTICULARS (INR Mn) FY19 FY20 H1-FY21 EQUITY 4,303 4,601 5,540 Non-Current Assets 4,143 5,591 5,576 a) Equity Share Capital 121 121 a) Property, Plant and Equipment 2,055 2,034 3,738 121 b) Capital Work In Progress 573 1,761 117 b) O
Slide 23: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) 12,000 10,491 1,500 12.46% 14.00% 10,000 8,922 1,200 12.00% 8,000 7,228 7.70% 10.00% 900 1,307 5,469 8.00% 6,000 5.16% 600 6.00% 4,000 687 1.74% 4.00% 2,000 300 282 2.00% - - 126 0.00% FY17 FY18 FY19 F
Slide 24: Capital Markets
Capital Markets 115% 95% 75% 55% 35% 15% -5% -25% -45% Oct-19 Nov-19 Dec-19 Jan-20 Feb-20 Mar-20 Apr-20 May-20 Jun-20 Jul-20 Aug-20 Sep-20 Camlin Fine Sciences SENSEX Price Data (30th September, 2020) INR Shareholding Pattern as on 30th September, 2020 Face Value 1.0 Promoters 22.73% Market Price 11
Slide 25: Disclaimer
Disclaimer Camlin Fine Sciences Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all e
Camlin Fine Sciences — Q2 FY2021 Earnings Presentation on 6ix